GlassScriptPhysician profile
Imad Asaad
NPI 1669725057
$141,060.13
in general payments reported to CMS, 2019-2025
28 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2021: $14.04 · 2022: $441 · 2023: $1,730 · 2024: $31K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Travel and Lodging: $11K · Food and Beverage: $8,857 · Consulting Fee: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,475.00 |
| Travel and Lodging | $10,976.27 |
| Food and Beverage | $8,856.84 |
| Consulting Fee | $1,057.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $91,875.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $31,501.96 | 2022-2025 | Wegovy |
| Gilead Sciences, INC. | $12,902.67 | 2022-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $1,779.18 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $505.51 | 2023-2025 | Entyvio, Gattex |
| Genzyme Corporation | $410.22 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $313.41 | 2019-2025 | |
| Janssen Biotech, INC. | $268.13 | 2023-2025 | Stelara, Tremfya, Remicade |
| Ipsen Biopharmaceuticals, INC | $253.25 | 2024 | Iqirvo, Bylvay |
| Medtronic, INC. | $186.77 | 2022-2025 | Barrx, Pillcam |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.09 | 2023-2025 | Trulance, Xifaxan |
| Lilly USA, LLC | $109.71 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $99.84 | 2023-2025 | Zenpep |
| W. L. Gore & Associates, INC. | $96.23 | 2022 | |
| Celgene Corporation | $95.62 | 2023-2024 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $88.49 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $73.85 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $59.92 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $53.03 | 2024 | Voquezna |
| Vivus LLC | $51.47 | 2025 | Qsymia |
| Nestle Healthcare Nutrition INC. | $38.99 | 2023 | |
| Merck Sharp & Dohme LLC | $36.50 | 2023-2024 | Zerbaxa, Recarbrio, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.23 | 2023-2024 | Cyltezo |
| Daiichi Sankyo INC. | $27.73 | 2023 | Injectafer |
| Sandoz INC. | $18.59 | 2024 | Hyrimoz |
| Tetraphase Pharmaceuticals, INC. | $14.71 | 2019 | |
| Braintree Laboratories, INC. | $14.23 | 2025 | Suflave, Sutab |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Asaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.